ArticleThe FEBS journal2007
Crystal structures of a bacterial 6-phosphogluconate dehydrogenase reveal aspects of specificity, mechanism and mode of inhibition by analogues of high-energy reaction intermediates.
Article in The FEBS journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Catalytic Properties of NADP-Reducing Enzymes fromBiomolecules · 2026Article
- Identification, functional characterization, and structural analysis of an atypical l-threonate 3-dehydrogenase.The Journal of biological chemistry · 2026Article
- Biochemical and functional properties of vesicles from planktonic and biofilm phenotypes of Limosilactobacillus reuteri DSM 17938.Scientific reports · 2025Article
- Crystal Structures of 6-Phosphogluconate Dehydrogenase fromJournal of microbiology and biotechnology · 2023Article
- Structure ofInternational journal of molecular sciences · 2023Article
- 6-Phosphogluconate dehydrogenase and its crystal structures.Acta crystallographica. Section F, Structural biology communications · 2022Review
- In Vitro and In Silico Approaches for the Evaluation of Antimicrobial Activity, Time-Kill Kinetics, and Anti-Biofilm Potential of Thymoquinone (2-Methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione) against Selected Human Pathogens.Antibiotics (Basel, Switzerland) · 2022Article
- Biochemical and structural insights into 6-phosphogluconate dehydrogenase from Leishmania donovani.Applied microbiology and biotechnology · 2021Article
- Structural basis for the catalytic mechanism and α-ketoglutarate cooperativity of glutamate dehydrogenase.The Journal of biological chemistry · 2018Article
- Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.Bioorganic & medicinal chemistry · 2010Article
- Identification, Cloning, and Characterization of l-Phenylserine Dehydrogenase from Pseudomonas syringae NK-15.Enzyme research · 2010Article
- Overexpression and simple purification of the Thermotoga maritima 6-phosphogluconate dehydrogenase in Escherichia coli and its application for NADPH regeneration.Microbial cell factories · 2009Article
- Geobacillus stearothermophilus 6-phosphogluconate dehydrogenase complexed with 6-phosphogluconate.Acta crystallographica. Section F, Structural biology and crystallization communications · 2009Article
- Crystal structure of Saccharomyces cerevisiae 6-phosphogluconate dehydrogenase Gnd1.BMC structural biology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Crystal structures of recombinant Lactococcus lactis 6-phosphogluconate dehydrogenase (LlPDH) in complex with substrate, cofactor, product and inhibitors have been determined. LlPDH shares significant sequence identity with the enzymes from sheep liver and the protozoan parasite Trypanosoma brucei for which structures have been reported. Comparisons indicate that the key residues in the active site are highly conserved, as are the interactions with the cofactor and the product ribulose 5-phosphate. However, there are differences in the conformation of the substrate 6-phosphogluconate which may reflect distinct states relevant to catalysis. Analysis of the complex formed with the potent inhibitor 4-phospho-d-erythronohydroxamic acid, suggests that this molecule does indeed mimic the high-energy intermediate state that it was designed to. The analysis also identified, as a contaminant by-product of the inhibitor synthesis, 4-phospho-d-erythronamide, which binds in similar fashion. LlPDH can now serve as a model system for structure-based inhibitor design targeting the enzyme from Trypanosoma species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.